Mucosal neuroimmune mechanisms in gastro-oesophageal reflux disease (GORD) pathogenesis

J Gastroenterol. 2024 Mar;59(3):165-178. doi: 10.1007/s00535-023-02065-9. Epub 2024 Jan 14.

Abstract

Gastro-oesophageal reflux disease (GORD) is a chronic condition characterised by visceral pain in the distal oesophagus. The current first-line treatment for GORD is proton pump inhibitors (PPIs), however, PPIs are ineffective in a large cohort of patients and long-term use may have adverse effects. Emerging evidence suggests that nerve fibre number and location are likely to play interrelated roles in nociception in the oesophagus of GORD patients. Simultaneously, alterations in cells of the oesophageal mucosa, namely epithelial cells, mast cells, dendritic cells, and T lymphocytes, have been a focus of GORD research for several years. The oesophagus of GORD patients exhibits both macro- and micro-inflammation as a response to chronic acidic reflux at the epithelium. In other conditions of the GI tract, such as IBS and IBD, well-characterised bidirectional processes between immune cells and mucosal nerve fibres contribute to pathogenesis and symptom generation. Sensory alterations in these conditions such as nerve fibre outgrowth and hypersensitivity can be driven by inflammatory processes, which promote visceral pain signalling. This review will examine what is currently known of the molecular pathways linking inflammation and sensory perception leading to the development of GORD symptoms and explore potentially relevant mechanisms in other GI regions which may indicate new areas in GORD research.

Keywords: Gastro-oesophageal reflux disease; Mucosal immunity; Neuroimmune.

Publication types

  • Review

MeSH terms

  • Gastroesophageal Reflux*
  • Humans
  • Inflammation
  • Neuroimmunomodulation
  • Proton Pump Inhibitors
  • Visceral Pain*

Substances

  • Proton Pump Inhibitors